Altogether, the use of a safe PCSK9 inhibitor strategy (mAb or siRNA) in combination with statins and possibly ezetimibe should drastically reduce circulating LDL-C levels (137), while enhancing the levels of cell surface LDLR and MHC-I to possibly provide some protection against tumor growth and/or metastasis. This evidence concerns the gene PCSK9 and neoplasm.